ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
Conference Call Scheduled for May 9, 2024, at 4:30 p.m. ET
電話會議定於美國東部時間2024年5月9日下午 4:30 舉行
RAMSEY, N.J. and BOCA RATON, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2024 financial results on May 9, 2024, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.
新澤西州拉姆西和佛羅里達州博卡拉頓，2024年5月2日（GLOBE NEWSWIRE）——致力於製造、營銷和開發特種生物製劑的端到端商業生物製藥公司ADMA Biologics, Inc.（納斯達克股票代碼：ADMA）（“ADMA” 或 “公司”）今天宣佈，繼美國之後，將於2024年5月9日公佈2024年第一季度財務業績金融市場關閉。ADMA的管理團隊將在美國東部時間當天下午 4:30 主持電話會議和網絡音頻直播，討論其財務業績和其他公司最新情況。
To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call).
要無縫訪問電話會議，參與者需要註冊電話會議 這裏 接收撥入號碼和唯一的 PIN。建議您在活動開始前大約 10 分鐘加入（儘管您可以在通話期間隨時撥號）。
Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under "Events & Webcasts" in the investor section of the Company's website at https://ir.admabiologics.com/events-webcasts.
鼓勵在電話會議期間不會提問的與會者收聽網絡直播 這裏。該活動的存檔重播將在公司網站投資者欄目的 “活動與網絡直播” 下提供 https://ir.admabiologics.com/events-webcasts。
About ADMA Biologics, Inc. (ADMA)
關於 ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products. ADMA's mission is to manufacture, market and develop specialty biologics and human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.
ADMA Biologics是一家端到端的商業生物製藥公司，致力於製造、營銷和開發特種生物製劑，用於治療有感染風險的免疫缺陷患者和其他面臨某些傳染病風險的患者。ADMA目前生產和銷售三種經美國食品藥品監督管理局（FDA）批准的血漿衍生生物製劑，用於治療免疫缺陷和預防某些傳染病：BIVIGAM （靜脈注射免疫球蛋白，人用）用於治療原發性體液免疫缺陷（PI）；ASCENIV（靜脈注射免疫球蛋白，人用 — slra 10% 液體）用於治療 PI；NABI-HB （乙型肝炎免疫球蛋白，人類）可增強對乙型肝炎病毒的免疫力。ADMA在其位於佛羅里達州博卡拉頓的經美國食品藥品管理局許可的血漿分餾和純化設施生產其免疫球蛋白產品。通過其ADMA BioCenters子公司，ADMA還作爲經美國食品藥品管理局批准的源血漿採集器在美國運營，該公司爲生產其產品提供血漿。ADMA的使命是製造、銷售和開發針對利基患者群體的特殊生物製劑和人體免疫球蛋白，用於治療和預防某些傳染病，並管理患有潛在免疫缺陷或可能因其他醫療原因而免疫受損的免疫受損患者群體。ADMA 擁有衆多與其產品和候選產品的各個方面相關的美國和外國專利。欲了解更多信息，請訪問 www.admabilogics.com。
INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com
投資者關係聯繫人：
米歇爾·帕帕納斯托斯
Argot Partners高級董事總經理 | 212-600-1902 | michelle@argotpartners.com
譯文內容由第三人軟體翻譯。